A survey of current practices of physicians who treat adductor spasmodic dysphonia in the U.S.

Ear, Nose and Throat Journal

Volumn 88, Issue 5, 2009, Pages

  Chang, Christopher Y ^a   Chabot, Peter ^b   Walz, Christopher M ^c  

^a PLC   (United States)

^b Minimax Consulting   (United States)

^c Throat and Facial Plastic Surgery Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DENERVATION; ELECTROMYOGRAPHY; HEALTH SURVEY; LARYNGOSCOPY; QUESTIONNAIRE; REINNERVATION; SPASMODIC DYSPHONIA; UNITED STATES;

EID: 66349091883     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sulica L. Contemporary management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg 2004; 12 (6): 543-548 (Pubitemid 39565212)
2. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients. Laryngoscope 1998; 108 (10): 1435-1441 (Pubitemid 28465236)
3. Koufman JA, Rees CJ, Halum SL, Blalock D. Treatment of adductor-type spasmodic dysphonia by surgical myectomy: A preliminary report. Ann Otol Rhinol Laryngol 2006; 115 (2): 97-102. (Pubitemid 43297294)
4. Chhetri DK, Mendelsohn AH, Blumin JH, Berke GS. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope 2006; 116 (4): 635-642 (Pubitemid 44318078)
5. Isshiki N, Haji T, Yamamoto Y, Mahieu HF. Thyroplasty for adductor spasmodic dysphonia: Further experiences. Laryngoscope 2001; 111 (4 Pt 1): 615-621 (Pubitemid 32295273)
6. Chan SW, Baxter M, Oates J, Yorston A. Long-term results of type II thyroplasty for adductor spasmodic dysphonia. Laryngoscope 2004; 114 (9): 1604-1608 (Pubitemid 39278879)
7. Thomas JP, Siupsinskiene N. Frozen versus fresh reconstituted botox for laryngeal dystonia. Otolaryngol Head Neck Surg 2006; 135 (2): 204-208 (Pubitemid 44142147)
8. Zwillinger D, Kokoska S. CRC Standard Probability and Statistics Tables and Formulae. Boca Raton, Fla.:Chapman & Hall/CRC; 2000:146.
9. Andrews D, Nonnecke B, Preece J. Conducting research on the Internet: Online survey design, development and implementation guidelines. Int J Hum Comput Interact 2003; 16 (2): 185-210.
10. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997; 50 (10): 1129-1136
11. Watts C, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): A systematic Cochrane review. Clin Rehabil 2006; 20 (2): 112-122 (Pubitemid 43379870)
12. Blitzer A, Brin MF. Laryngeal dystonia: A series with botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991; 100 (2): 85-89
13. Casserly P, Timon C. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia. J Laryngol Otol 2008; 122 (1): 52-56
14. Cantarella G, Berlusconi A, Maraschi B, et al. Botulinum toxin injection and airflow stability in spasmodic dysphonia. Otolaryngol Head Neck Surg 2006; 134 (3): 419-423 (Pubitemid 43267241)
15. Lundy DS, Lu FL, Casiano RR, Xue JW. The effect of patient factors on response outcomes to Botox treatment of spasmodic dysphonia. J Voice 1998; 12 (4): 460-466 (Pubitemid 29070018)
16. Ford CN, Bless DM, Patel NY. Botulinum toxin treatment of spasmodic dysphonia: Techniques, indications, efficacy. J Voice 1992; 6 (4): 370-376
17. Truong DD, Bhidayasiri R. Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: Comparing different botulinum toxin preparations. Eur J Neurol 2006; 13 (Suppl 1): 36-41.
18. Chang CY, Chabot P, Thomas JP. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. Otolaryngol Head Neck Surg 2007; 136 (6): 894-899 (Pubitemid 46850773)
19. Damrose JF, Goldman SN, Groessl EJ, Orloff LA. The impact of long-term botulinum toxin injections on symptom severity in patients with spasmodic dysphonia. J Voice 2004; 18 (3): 415-422 (Pubitemid 39164293)
20. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140 (11): 1351-1354 (Pubitemid 39473635)
21. Boutsen F, Cannito MP, Taylor M, Bender B. Botox treatment in adductor spasmodic dysphonia: A meta-analysis. J Speech Lang Hear Res 2002; 45 (3): 469-481 (Pubitemid 34596316)